國家衛生研究院 NHRI:Item 3990099045/3018

NHRI > National Institute of Cancer Research > Jacqueline Whang-Peng(1996-2007) > Periodical Articles > Item 3990099045/3018

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/3018

Title:	A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin combination chemotherapy for inoperable non-small-cell lung cancer
Authors:	Chen, YM;Perng, RP;Yang, KY;Lin, WC;Wu, HW;Liu, JM;Tsai, CM;Whang-Peng, J
Contributors:	National Institute of Cancer Research
Abstract:	A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin (TIEP) chemotherapy was conducted in patients with chemonaive inoperable non-small-cell lung cancer (NSCLC) to assess response and toxicity. From October 1997 to August 1998, 19 patients were treated. The treatment schema included tamoxifen 60 mg twice daily by mouth on days 1 to 3, ifosfamide 3 g/m(2) intravenous infusion (IV) 60 minutes with mesna on day 2, epirubicin 50 mg/m(2) IV bolus on day 2, and cisplatin 60 mg/m(2) IV 60 minutes on day 2 every 4 weeks for up to six cycles. All patients were evaluable for response and toxicity. The major toxicity was myelosuppression; grade 3 or 4 leukopenia or neutropenia occurred in 14 of 19 (73.7%) patients during treatment, and 6 patients (31.6%) experienced fever in association with the neutropenia; no toxic deaths occurred. Grade 3 anemia occurred in six patients (31.6%) during the treatment. Grade 3 or 4 nausea/vomiting occurred in only one patient. Toxicities other than neutropenia and anemia were minimal. After two cycles of treatment, 9 of 19 patients attained a partial response (47.4%, 95% confidence interval 24.9%-69.9%) in this study. The median time to disease progression was 6 months and median survival time was 12 months. We conclude that TIEP is an active combination regimen with an acceptable toxicity profile in Chinese patients with inoperable NSCLC.
Keywords:	Oncology
Date:	2000-02
Relation:	American Journal of Clinical Oncology. 2000 Feb;23(1):13-17.
Link to:	http://dx.doi.org/10.1097/00000421-200002000-00003
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0277-3732&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000085253400003
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0034122378
Appears in Collections:	[Jacqueline Whang-Peng(1996-2007)] Periodical Articles [Ming Jacqueline Liu(1996-2007)] Periodical Articles

Files in This Item:

File	Description	Size	Format
ISI000085253400003.pdf		570Kb	Adobe PDF	279	View/Open

Loading...